Video - Results from #10

Crawford's Corner Video Channel VL

EV-302 Trial Establishes Treatment Standard for Urothelial Carcinoma - Daniel Petrylak Details David Crawford discusses advancements in advanced urothelial cancer treatment with Daniel Petrylak. Dr. Petrylak highlights the success of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, combined with pembrolizumab. This combination demonstrates significant improvements in response rates and survival compared to standard chemotherapy, with a 30% complete response rate and d...
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak Details David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases....